Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Human Genome Sciences has said a phase Ib clinical trial demonstrates that HGS-ETR1 in combination with gemcitabine and cisplatin was well tolerated and could be administered safely in patients with advanced solid tumors.
Subscribe to our email newsletter
“Preclinical studies have shown that adding HGS-ETR1 to gemcitabine and cisplatin results in increased cytotoxicity. These data warrant further study of HGS-ETR1 in combination with chemotherapeutic agents in phase II trials to evaluate its potential for use in the treatment of specific cancers,” said Professor Dr Elisabeth de Vries, head of the division of medical oncology, Groningen University Hospital, The Netherlands.
The primary objective of the study, which is being conducted in the Netherlands, is to evaluate the safety and tolerability of escalating doses of the combination of gemcitabine and cisplatin.
Human Genome Sciences commented that the maximum tolerated dose of HGS-ETR1 has not yet been reached and patients will continue to be enrolled in the phase Ib study.